FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3177675558> ?p ?o ?g. }

• W3177675558 endingPage "e27980" @default.
• W3177675558 startingPage "e27980" @default.
• W3177675558 abstract "Background Participation in quality controls, also called external quality assessment (EQA) schemes, is required for the ISO15189 accreditation of the Medical Centers of Human Genetics. However, directives on the minimal frequency of participation in genetic quality control schemes are lacking or too heterogeneous, with a possible impact on health care quality. Objective The aim of this project is to develop Belgian guidelines on the frequency of participation in quality controls for genetic testing in the context of rare diseases. Methods A group of experts analyzed 90 EQA schemes offered by accredited providers and focused on analyses used for the diagnosis of rare diseases. On that basis, the experts developed practical recommendations about the minimal frequencies of participation of the Medical Centers of Human Genetics in quality controls and how to deal with poor performances and change management. These guidelines were submitted to the Belgian Accreditation Body and then reviewed and approved by the Belgian College of Human Genetics and Rare Diseases and by the National Institute for Health and Disability Insurance. Results The guidelines offer a decisional algorithm for the minimal frequency of participation in human genetics EQA schemes. This algorithm has been developed taking into account the scopes of the EQA schemes, the levels of experience, and the annual volumes of the Centers of Human Genetics in the performance of the tests considered. They include three key principles: (1) the recommended annual assessment of all genetic techniques and technological platforms, if possible through EQAs covering the technique, genotyping, and clinical interpretation; (2) the triennial assessment of the genotyping and interpretation of specific germline mutations and pharmacogenomics analyses; and (3) the documentation of actions undertaken in the case of poor performances and the participation to quality control the following year. The use of a Bayesian statistical model has been proposed to help the Centers of Human Genetics to determine the theoretical number of tests that should be annually performed to achieve a certain threshold of performance (eg, a maximal error rate of 1%). Besides, the guidelines insist on the role and responsibility of the national public health authorities in the follow-up of the quality of analyses performed by the Medical Centers of Human Genetics and in demonstrating the cost-effectiveness and rationalization of participation frequency in these quality controls. Conclusions These guidelines have been developed based on the analysis of a large panel of EQA schemes and data collected from the Belgian Medical Centers of Human Genetics. They are applicable to other countries and will facilitate and improve the quality management and financing systems of the Medical Centers of Human Genetics." @default.
• W3177675558 created "2021-07-19" @default.
• W3177675558 creator A5000397696 @default.
• W3177675558 creator A5001940268 @default.
• W3177675558 creator A5008869133 @default.
• W3177675558 creator A5012839649 @default.
• W3177675558 creator A5019374336 @default.
• W3177675558 creator A5023849845 @default.
• W3177675558 creator A5024297128 @default.
• W3177675558 creator A5028489583 @default.
• W3177675558 creator A5028526077 @default.
• W3177675558 creator A5030540130 @default.
• W3177675558 creator A5034130006 @default.
• W3177675558 creator A5038750535 @default.
• W3177675558 creator A5038919034 @default.
• W3177675558 creator A5040475489 @default.
• W3177675558 creator A5040587234 @default.
• W3177675558 creator A5050779836 @default.
• W3177675558 creator A5064590176 @default.
• W3177675558 creator A5066647950 @default.
• W3177675558 creator A5072930110 @default.
• W3177675558 creator A5074442977 @default.
• W3177675558 date "2021-07-12" @default.
• W3177675558 modified "2023-09-23" @default.
• W3177675558 title "Frequency of Participation in External Quality Assessment Programs Focused on Rare Diseases: Belgian Guidelines for Human Genetics Centers" @default.
• W3177675558 cites W1499919581 @default.
• W3177675558 cites W1980355960 @default.
• W3177675558 cites W1995559981 @default.
• W3177675558 cites W2047295402 @default.
• W3177675558 cites W2061361258 @default.
• W3177675558 cites W2095487434 @default.
• W3177675558 cites W2123386536 @default.
• W3177675558 cites W2126121566 @default.
• W3177675558 cites W2128099173 @default.
• W3177675558 cites W2130562173 @default.
• W3177675558 cites W2133291901 @default.
• W3177675558 cites W2141322774 @default.
• W3177675558 cites W2280000445 @default.
• W3177675558 cites W2333001937 @default.
• W3177675558 cites W2547003852 @default.
• W3177675558 cites W2602238011 @default.
• W3177675558 cites W2611574484 @default.
• W3177675558 cites W2781564588 @default.
• W3177675558 cites W2782644058 @default.
• W3177675558 cites W2792407191 @default.
• W3177675558 cites W2801770572 @default.
• W3177675558 cites W2890454147 @default.
• W3177675558 cites W2895995729 @default.
• W3177675558 cites W2912717867 @default.
• W3177675558 cites W2921843304 @default.
• W3177675558 cites W2969876541 @default.
• W3177675558 cites W2991592211 @default.
• W3177675558 cites W4253999279 @default.
• W3177675558 doi "https://doi.org/10.2196/27980" @default.
• W3177675558 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8314149" @default.
• W3177675558 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34255700" @default.
• W3177675558 hasPublicationYear "2021" @default.
• W3177675558 type Work @default.
• W3177675558 sameAs 3177675558 @default.
• W3177675558 citedByCount "0" @default.
• W3177675558 crossrefType "journal-article" @default.
• W3177675558 hasAuthorship W3177675558A5000397696 @default.
• W3177675558 hasAuthorship W3177675558A5001940268 @default.
• W3177675558 hasAuthorship W3177675558A5008869133 @default.
• W3177675558 hasAuthorship W3177675558A5012839649 @default.
• W3177675558 hasAuthorship W3177675558A5019374336 @default.
• W3177675558 hasAuthorship W3177675558A5023849845 @default.
• W3177675558 hasAuthorship W3177675558A5024297128 @default.
• W3177675558 hasAuthorship W3177675558A5028489583 @default.
• W3177675558 hasAuthorship W3177675558A5028526077 @default.
• W3177675558 hasAuthorship W3177675558A5030540130 @default.
• W3177675558 hasAuthorship W3177675558A5034130006 @default.
• W3177675558 hasAuthorship W3177675558A5038750535 @default.
• W3177675558 hasAuthorship W3177675558A5038919034 @default.
• W3177675558 hasAuthorship W3177675558A5040475489 @default.
• W3177675558 hasAuthorship W3177675558A5040587234 @default.
• W3177675558 hasAuthorship W3177675558A5050779836 @default.
• W3177675558 hasAuthorship W3177675558A5064590176 @default.
• W3177675558 hasAuthorship W3177675558A5066647950 @default.
• W3177675558 hasAuthorship W3177675558A5072930110 @default.
• W3177675558 hasAuthorship W3177675558A5074442977 @default.
• W3177675558 hasBestOaLocation W31776755581 @default.
• W3177675558 hasConcept C104317684 @default.
• W3177675558 hasConcept C106436119 @default.
• W3177675558 hasConcept C111472728 @default.
• W3177675558 hasConcept C126322002 @default.
• W3177675558 hasConcept C138885662 @default.
• W3177675558 hasConcept C142724271 @default.
• W3177675558 hasConcept C151730666 @default.
• W3177675558 hasConcept C160735492 @default.
• W3177675558 hasConcept C17744445 @default.
• W3177675558 hasConcept C19527891 @default.
• W3177675558 hasConcept C199539241 @default.
• W3177675558 hasConcept C2778618615 @default.
• W3177675558 hasConcept C2779343474 @default.
• W3177675558 hasConcept C2779530757 @default.
• W3177675558 hasConcept C2780673598 @default.
• W3177675558 hasConcept C509550671 @default.

• next